The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib/II trial (N16IMC, NCT03003637).
 
Charlotte L. Zuur
Research Funding - Bristol-Myers Squibb (Inst)
 
Joris B. W. Elbers
No Relationships to Disclose
 
Anne van der Leun
No Relationships to Disclose
 
Michiel van den Brekel
No Relationships to Disclose
 
Bing Tan
No Relationships to Disclose
 
Bas Jasperse
No Relationships to Disclose
 
Wouter Vogel
No Relationships to Disclose
 
Laura Smit
No Relationships to Disclose
 
Stefan M. Willems
No Relationships to Disclose
 
Abrahim Al-Mamgani
No Relationships to Disclose
 
Jasper Nijkamp
No Relationships to Disclose
 
Ton Schumacher
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - AIMM Therapeutics; Kite, a Gilead company; Neon Therapeutics
Honoraria - AIMM Therapeutics; Neon Therapeutics
Research Funding - Bristol-Myers Squibb; Merck
Patents, Royalties, Other Intellectual Property - -
 
Christian U. Blank
Stock and Other Ownership Interests - Verastem
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
J. P. De Boer
Research Funding - Merck (Inst)
 
John B. A. G. Haanen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst)